ALNOV:EPA
Novacyt SA
€0.36
arrow_downward
-1.92%(-0.0070) 1 日
4月28日, 14:53:10 GMT+2 · EUR
search
すべての記号
1 日
5 日
1 か月
6 か月
年初来
1 年
5 年
最大
| 記号 | 価格 | 変化 | 変化率 |
|---|
insights_autoALNOV の上位の分析情報を生成しています...
始値
€0.36
高値
€0.36
安値
€0.36
時価総額
2627.25万
平均出来高
11.33万
取引量
7.40万
52 週高値
€0.74
52 週安値
€0.36
EPS
-€0.50
発行済株式数
7258.81万
従業員数
234
ニュース記事
ウェブの情報から
PR Newswire UK
·
32 分前
NYSE Content Update: Joby Aviation Rings Opening Bell Following NYC Test Flight
Trefis
·
54 分前
S&P 500 Stocks Trading At 52-Week High
プロフィール
Novacyt Group is an Anglo-French biotechnology group focused on clinical diagnostics, with offices in Camberley, Surrey, United Kingdom and Vélizy-Villacoublay, France. The company produces in vitro and molecular diagnostic tests, supplying assays and reagents worldwide. Its business units include Primerdesign, Microgen Bioproducts and Lab21 Healthcare.
In January 2020 the company announced that its molecular diagnostics division, Primerdesign, had launched a molecular test for the 2019 strain of SARSr-CoV. The test was approved as eligible for procurement under the World Health Organization's Emergency Use Listing process in April 2020, meaning that the test could be supplied by the United Nations and other procurement agencies supporting the COVID-19 response. In the same month Novacyt announced a collaboration with AstraZeneca, GlaxoSmithKline and the University of Cambridge to support the UK in its COVID-19 national screening programme at a new testing laboratory at the university's Anne McLaren laboratory. Wikipedia
Novacyt SA について